VRCA ▼ -3.1% - Verrica Pharmaceuticals Inc. $VRCA - Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 27-AUG-2026 08:00 AM ET